{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T17:48:25Z","timestamp":1777657705451,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s11926-021-01008-8","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:09:28Z","timestamp":1620043768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION): 10-Year Update"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7216-677X","authenticated-orcid":false,"given":"Doruk","family":"Erkan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savino","family":"Sciascia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Laura","family":"Bertolaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"APS ACTION Executive Committee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danieli","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Gerosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Petri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Roubey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Tektonidou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,1]]},"reference":[{"issue":"2","key":"1008_CR1","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","volume":"4","author":"S Miyakis","year":"2006","unstructured":"Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4(2):295\u2013306.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"1008_CR2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0961203310395053","volume":"20","author":"D Erkan","year":"2011","unstructured":"Erkan D, Derksen R, Levy R, Machin S, Ortel T, Pierangeli S, et al. Antiphospholipid syndrome clinical research task force report. Lupus. 2011;20(2):219\u201324.","journal-title":"Lupus."},{"issue":"7","key":"1008_CR3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0961203312437810","volume":"21","author":"D Erkan","year":"2012","unstructured":"Erkan D, Lockshin MD, APS ACTION members. APS ACTION-AntiPhospholipid Syndrome Alliance for clinical trials and international networking. Lupus. 2012;21(7):695\u20138.","journal-title":"Lupus."},{"issue":"9","key":"1008_CR4","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.40901","volume":"71","author":"A Duarte-Garc\u00eda","year":"2019","unstructured":"Duarte-Garc\u00eda A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheum. 2019;71(9):1545\u201352.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1008_CR5","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/art.41401","volume":"72","author":"M Radin","year":"2020","unstructured":"Radin M, Sciascia S, Bazzan M, Bertero T, Carignola R, Montabone E, et al. Antiphospholipid syndrome is still a rare disease-estimated prevalence in the Piedmont and Aosta Valley regions of Northwest Italy: comment on the article by Duarte-Garc\u00eda et al. Arthritis Rheum. 2020;72(10):1774\u20136.","journal-title":"Arthritis Rheum"},{"issue":"9","key":"1008_CR6","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1177\/0961203315572714","volume":"24","author":"CB Chighizola","year":"2015","unstructured":"Chighizola CB, Andreoli L, de Jesus GR, Banzato A, Pons-Estel GJ, Erkan D, et al. The association between antiphospholipid antibodies and pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Lupus. 2015;24(9):980\u20134.","journal-title":"Lupus."},{"issue":"11","key":"1008_CR7","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","volume":"65","author":"L Andreoli","year":"2013","unstructured":"Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the literature. Arthritis Care Res. 2013;65(11):1869\u201373.","journal-title":"Arthritis Care Res"},{"issue":"11","key":"1008_CR8","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1136\/annrheumdis-2014-205663","volume":"74","author":"S Sciascia","year":"2015","unstructured":"Sciascia S, Sanna G, Khamashta MA, Cuadrado MJ, Erkan D, Andreoli L, et al. The estimated frequency of antiphospholipid antibodies in young adults with cerebrovascular events: a systematic review. Ann Rheum Dis. 2015;74(11):2028\u201333.","journal-title":"Ann Rheum Dis"},{"key":"1008_CR9","doi-asserted-by":"publisher","unstructured":"Sevim E, Zisa D, Andrade D, Sciascia S, Pengo V, Tektonidou MG, et al. Characteristics of antiphospholipid antibody positive patients in AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking. Arthritis Care Res. 2020. https:\/\/doi.org\/10.1002\/acr.24468 Online ahead of print.","DOI":"10.1002\/acr.24468"},{"issue":"1","key":"1008_CR10","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/acr.23584","volume":"71","author":"O Unlu","year":"2019","unstructured":"Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, et al. The impact of systemic lupus erythematosus on the clinical phenotype of antiphospholipid antibody-positive patients: results from the AntiPhospholipid Syndrome Alliance for clinical trials and InternatiOnal Clinical Database and Repository. Arthritis Care Res. 2019;71(1):134\u201341.","journal-title":"Arthritis Care Res"},{"key":"1008_CR11","first-page":"961203320940776","volume":"23","author":"S Zuily","year":"2020","unstructured":"Zuily S, Clerc-Urm\u00e8s I, Bauman C, Andrade D, Sciascia S, et al. Cluster analysis for the identification of clinical phenotypes among antiphospholipid antibody-positive patients from the APS ACTION Registry. Lupus. 2020;23:961203320940776.","journal-title":"Lupus."},{"key":"1008_CR12","doi-asserted-by":"crossref","unstructured":"Gkrouzman E, Sevim E, Finik J, Andrade D, Pengo V, et al. Antiphospholipid antibody profile stability over time: prospective results from APS ACTION Clinical Database and Repository. J Rheumatol. 2020:jrheum.200513.","DOI":"10.3899\/jrheum.200513"},{"issue":"3","key":"1008_CR13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.semarthrit.2019.04.009","volume":"49","author":"M Radin","year":"2019","unstructured":"Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, et al. The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort. Semin Arthritis Rheum. 2019;49(3):464\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"1008_CR14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/1471-0528.15469","volume":"126","author":"GR de Jes\u00fas","year":"2019","unstructured":"de Jes\u00fas GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, et al. Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG. 2019;126(5):656\u201361.","journal-title":"BJOG."},{"issue":"25","key":"1008_CR15","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1182\/bloodadvances.2017008185","volume":"1","author":"WG Jackson","year":"2017","unstructured":"Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT, Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320\u20134.","journal-title":"Blood Adv"},{"issue":"Suppl 2","key":"1008_CR16","first-page":"777","volume":"13","author":"IJ Mackie","year":"2015","unstructured":"Mackie IJ, Pengo V, Gray E, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking core laboratory validation exercise: an international performance assessment of lupus anticoagulant (LA) tests using standardized methods and reagents. J Thromb Haemost. 2015;13(Suppl 2):777 (abstract).","journal-title":"J Thromb Haemost"},{"issue":"12","key":"1008_CR17","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jth.14596","volume":"17","author":"M Efthymiou","year":"2019","unstructured":"Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, et al. Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository. J Thromb Haemost. 2019;17(12):2069\u201380.","journal-title":"J Thromb Haemost"},{"key":"1008_CR18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.thromres.2019.01.010","volume":"175","author":"S Sciascia","year":"2019","unstructured":"Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, et al. The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis. Thromb Res. 2019;175:32\u20136.","journal-title":"Thromb Res"},{"issue":"3","key":"1008_CR19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0961203317724219","volume":"27","author":"D Erkan","year":"2018","unstructured":"Erkan D, Unlu O, Sciascia S, Belmont HM, Branch DW, Cuadrado MJ, et al. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27(3):399\u2013406.","journal-title":"Lupus."},{"key":"1008_CR20","doi-asserted-by":"publisher","unstructured":"Gkrouzman E, Barbhaiya M, Erkan D, Lockshin MD. Reality check on antiphospholipid antibodies in COVID-19-associated coagulopathy. Arthritis Rheum. 2020. https:\/\/doi.org\/10.1002\/art.41472.","DOI":"10.1002\/art.41472"},{"key":"1008_CR21","unstructured":"Taghavi M, Barbhaiya M, Tektonidou M, Fortin P, Andrade D, et al. Descriptive analysis of biopsy-proven antiphospholipid antibody-associated nephropathy patients included in the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (\u201cRegistry\u201d) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/descriptive-analysis-of-biopsy-proven-antiphospholipid-antibody-associated-nephropathy-patients-included-in-the-antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-aps\/. Accessed December 25, 2020."},{"key":"1008_CR22","unstructured":"Barbhaiya M, Erkan D, Zuily S, Tektonidou M, Seshan S. Characterization of antiphospholipid antibody-associated nephropathy: an international survey of Renal Pathology Society Members [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https:\/\/acrabstracts.org\/abstract\/characterization-of-antiphospholipid-antibody-associated-nephropathy-an-international-survey-of-renal-pathology-society-members\/. Accessed December 25, 2020."},{"key":"1008_CR23","unstructured":"Sevim E, Unlu O, Andrade D, Banzato A, Tektonidou M, et al. First and recurrent thrombosis risk after 1897 patient-years of follow-up: prospective results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (\u201cRegistry\u201d) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https:\/\/acrabstracts.org\/abstract\/first-and-recurrent-thrombosis-risk-after-1897-patient-years-of-follow-up-prospective-results-from-antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-aps-action-cli\/. Accessed December 25, 2020."},{"key":"1008_CR24","unstructured":"Sevim E, Andrade D, Banzato A, Tektonidou M, Ugarte A, et al. Pregnancy outcomes of antiphospholipid antibody positive patients: prospective results from Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository (\u201cRegistry\u201d) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https:\/\/acrabstracts.org\/abstract\/pregnancy-outcomes-of-antiphospholipid-antibody-positive-patients-prospective-results-from-antiphospholipid-syndrome-alliance-for-clinical-trials-and-international-networking-aps-action-clinical-da\/. Accessed December 25, 2020."},{"issue":"7","key":"1008_CR25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","volume":"18","author":"A Tripodi","year":"2020","unstructured":"Tripodi A, Cohen H, Devreese KMJ. Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2020;18(7):1569\u201375.","journal-title":"J Thromb Haemost"},{"key":"1008_CR26","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","volume":"18","author":"KMJ Devreese","year":"2020","unstructured":"Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. Update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18:2828\u201339.","journal-title":"J Thromb Haemost"},{"issue":"13","key":"1008_CR27","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood-2018-04-848333","volume":"132","author":"V Pengo","year":"2018","unstructured":"Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018;132(13):1365\u201371.","journal-title":"Blood."},{"key":"1008_CR28","unstructured":"Ortel T. Anticoagulation withdrawal in in antiphospholipid syndrome. https:\/\/grantome.com\/grant\/NIH\/U34-HL123499-01. Accessed December 25, 2020."},{"issue":"10","key":"1008_CR29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11926-016-0611-y","volume":"18","author":"M Barbhaiya","year":"2016","unstructured":"Barbhaiya M, Andrade D, Erkan D. AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-year update. Curr Rheumatol Rep. 2016;18(10):64.","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"1008_CR30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13023-017-0755-5","volume":"13","author":"D Whicher","year":"2018","unstructured":"Whicher D, Philbin S, Aronson N. An overview of the impact of rare disease characteristics on research methodology. Orphanet J Rare Dis. 2018;13(1):14.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1008_CR31","first-page":"89","volume":"62","author":"H Dolfus","year":"2012","unstructured":"Dolfus H, L\u00e9vy N. Maladies rares, un champ de recherche \u201cexceptionnel\u201d [Rare diseases: an \u201cexceptional\u201d field of research. Interview by Catherine Holu\u00e9]. Rev Prat. 2012;62(1):89\u201390.","journal-title":"Rev Prat"},{"key":"#cr-split#-1008_CR32.1","doi-asserted-by":"crossref","unstructured":"Rodziewicz M, D'Cruz D, Gulliford M, Hazra N. The epidemiology of the antiphospholipid syndrome in the UK, 1990-2016 [abstract]. Arthritis Rheumatol. 2019","DOI":"10.1093\/rheumatology\/kez105.029"},{"key":"#cr-split#-1008_CR32.2","unstructured":"71 (suppl 10). https:\/\/acrabstracts.org\/abstract\/the-epidemiology-of-the-antiphospholipid-syndrome-in-the-uk-1990-2016\/. Accessed December 12, 2020."},{"issue":"19","key":"1008_CR33","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","volume":"131","author":"C Kearon","year":"2018","unstructured":"Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151\u201360.","journal-title":"Blood"},{"issue":"4","key":"1008_CR34","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/jth.14720","volume":"18","author":"S Miranda","year":"2020","unstructured":"Miranda S, Park J, Le Gal G, Piran S, Kherani S, Rodger MA, et al. Prevalence of confirmed antiphospholipid syndrome in 18\u201350 years unselected patients with first unprovoked venous thromboembolism. J Thromb Haemost. 2020;18(4):926\u201330.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1008_CR35","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/blood-2013-04-496257","volume":"122","author":"D Garcia","year":"2013","unstructured":"Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013;122(5):817\u201324.","journal-title":"Blood."},{"issue":"9","key":"1008_CR36","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/jth.14936","volume":"18","author":"TL Ortel","year":"2020","unstructured":"Ortel TL, Meleth S, Catellier D, Crowther M, Erkan D, Fortin PR, et al. Recurrent thrombosis in patients with antiphospholipid antibodies and an initial venous or arterial thromboembolic event: a systematic review and meta-analysis. J Thromb Haemost. 2020;18(9):2274\u201386.","journal-title":"J Thromb Haemost"},{"issue":"5","key":"1008_CR37","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2002-02-0441","volume":"101","author":"M Galli","year":"2003","unstructured":"Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101(5):1827\u201332.","journal-title":"Blood."},{"issue":"22","key":"1008_CR38","doi-asserted-by":"crossref","first-page":"3477","DOI":"10.1182\/blood-2014-11-611129","volume":"125","author":"J Gebhart","year":"2015","unstructured":"Gebhart J, Posch F, Koder S, Perkmann T, Quehenberger P, Zoghlami C, et al. Increased mortality in patients with the lupus anticoagulant: the Vienna Lupus Anticoagulant and Thrombosis Study (LATS). Blood. 2015;125(22):3477\u201383.","journal-title":"Blood."},{"issue":"17","key":"1008_CR39","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1182\/blood-2011-03-340232","volume":"118","author":"V Pengo","year":"2011","unstructured":"Pengo V, Ruffatti A, Legnani C, Testa S, Fierro T, Marongiu F, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood. 2011;118(17):4714\u20138.","journal-title":"Blood."},{"issue":"2","key":"1008_CR40","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1160\/TH13-06-0509","volume":"111","author":"S Sciascia","year":"2014","unstructured":"Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine\/prothrombin (aPS\/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111(2):354\u201364.","journal-title":"Thromb Haemost"},{"issue":"9","key":"1008_CR41","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1111\/jth.13389","volume":"14","author":"AS De Craemer","year":"2016","unstructured":"De Craemer AS, Musial J, Devreese KM. Role of anti-domain 1-\u03b22 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. 2016;14(9):1779\u201387.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"1008_CR42","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/jth.12722","volume":"12","author":"DR Arachchillage","year":"2014","unstructured":"Arachchillage DR, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Anti-protein C antibodies are associated with resistance to endogenous protein C activation and a severe thrombotic phenotype in antiphospholipid syndrome. J Thromb Haemost. 2014;12(11):1801\u20139.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"1008_CR43","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/art.41460","volume":"72","author":"Y Zuo","year":"2020","unstructured":"Zuo Y, Yalavarthi S, Gockman K, Madison JA, Gudjonsson JE, Kahlenberg JM, et al. Anti-neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome. Arthritis Rheum. 2020;72(12):2130\u20135.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"1008_CR44","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood.2019003863","volume":"135","author":"S Chaturvedi","year":"2020","unstructured":"Chaturvedi S, Braunstein EM, Yuan X, Yu J, Alexander A, Chen H, et al. Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2020;135(4):239\u201351.","journal-title":"Blood."},{"issue":"10","key":"1008_CR45","doi-asserted-by":"crossref","first-page":"102641","DOI":"10.1016\/j.autrev.2020.102641","volume":"19","author":"S Sciascia","year":"2020","unstructured":"Sciascia S, Radin M, Ramirez C. Evaluation of novel assays for the detection of autoantibodies in antiphospholipid syndrome. Autoimmun Rev. 2020;19(10):102641.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1008_CR46","doi-asserted-by":"crossref","first-page":"102450","DOI":"10.1016\/j.autrev.2019.102450","volume":"19","author":"CP Moritz","year":"2020","unstructured":"Moritz CP, Paul S, Stoevesandt O, Tholance Y, Camdensanche J-P, Antoine J-C. Autoantigenomics: holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases. Autoimmun Rev. 2020;19(2):102450.","journal-title":"Autoimmun Rev"},{"key":"1008_CR47","doi-asserted-by":"crossref","unstructured":"Anaya J-M, Leon KJ, Rojas M, et al. Progress towards precision medicine for lupus: the role of genetic biomarkers. Expert Rev Precis Med Drug Dev, 32, 119\u2013135.","DOI":"10.1080\/23808993.2018.1448266"},{"key":"1008_CR48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/PGPM.S205079","volume":"13","author":"E Lever","year":"2020","unstructured":"Lever E, Alves MR, Isenberg DA. Towards precision medicine in systemic lupus erythematosus. Pharmacogenomics Personalized Med. 2020;13:39\u201349.","journal-title":"Pharmacogenomics Personalized Med"},{"issue":"Database issue","key":"1008_CR49","doi-asserted-by":"crossref","first-page":"D1001","DOI":"10.1093\/nar\/gkt1229","volume":"42","author":"D Welter","year":"2014","unstructured":"Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 2014;42(Database issue):D1001\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1008_CR50","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/s41598-019-53111-7","volume":"9","author":"J H\u00f6glund","year":"2019","unstructured":"H\u00f6glund J, Rafati N, Rask-Andersen M, et al. Improved power and precision with whole genome sequencing data in genome-wide association studies of inflammatory biomarkers. Sci Rep. 2019;9(1):1684.","journal-title":"Sci Rep"},{"issue":"12","key":"1008_CR51","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1177\/0961203320950461","volume":"29","author":"H Cohen","year":"2020","unstructured":"Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, et al. 16th International Congress on Antiphospholipid Antibodies Task Force report on antiphospholipid syndrome treatment trends. Lupus. 2020;29(12):1571\u201393.","journal-title":"Lupus."},{"issue":"9","key":"1008_CR52","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1177\/0961203315576858","volume":"24","author":"MC Amigo","year":"2015","unstructured":"Amigo MC, Goycochea-Robles MV, Espinosa-Cuervo G, Medina G, Barrag\u00e1n-Garfias JA, Vargas A, et al. Development and initial validation of a damage index (DIAPS) in patients with thrombotic antiphospholipid syndrome (APS). Lupus. 2015;24(9):927\u201334.","journal-title":"Lupus."},{"issue":"1","key":"1008_CR53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3899\/jrheum.120873","volume":"40","author":"M Barbhaiya","year":"2013","unstructured":"Barbhaiya M, Erkan D. The optimal tool for assessment of organ damage in antiphospholipid syndrome. J Rheumatol. 2013;40(1):89.","journal-title":"J Rheumatol"},{"issue":"3","key":"1008_CR54","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0961203320901598","volume":"29","author":"AK Torricelli","year":"2020","unstructured":"Torricelli AK, Remia M, Ugolini-Lopes O, Bonfa E, Andrade D. \u0303 Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. Lupus. 2020;29(3):256\u201362.","journal-title":"Lupus."},{"issue":"7","key":"1008_CR55","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/rheumatology\/keaa172","volume":"59","author":"P Gaspar","year":"2020","unstructured":"Gaspar P, Cohen H, Isenberg D. The assessment of patients with the antiphospholipid antibody syndrome: where are we now? Rheumatology. 2020;59(7):1489\u201394.","journal-title":"Rheumatology."},{"issue":"1","key":"1008_CR56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/acr.23240","volume":"70","author":"SG Nantes","year":"2018","unstructured":"Nantes SG, Strand V, Su J, Touma Z. Comparison of the sensitivity to change of the 36-item short form health survey and the lupus quality of life measure using various definitions of minimum clinically important differences in patients with active systemic lupus erythematosus. Arthritis Care Res. 2018;70(1):125\u201333.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"1008_CR57","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1001\/archinte.162.10.1144","volume":"162","author":"SR Kahn","year":"2002","unstructured":"Kahn SR, Hirsch A, Shrier I. Effect of post-thrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002;162(10):1144\u20138.","journal-title":"Arch Intern Med"}],"updated-by":[{"DOI":"10.1007\/s11926-021-01034-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000}}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11926-021-01008-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-021-01008-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T07:55:00Z","timestamp":1744185300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11926-021-01008-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,1]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1008"],"URL":"https:\/\/doi.org\/10.1007\/s11926-021-01008-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s11926-021-01034-6","asserted-by":"object"}]},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,1]]},"assertion":[{"value":"23 March 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11926-021-01034-6","URL":"https:\/\/doi.org\/10.1007\/s11926-021-01034-6","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"45"}}